132 related articles for article (PubMed ID: 31375512)
21. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.
Yu J; Yu J; Wu X; Guo Q; Yin T; Cheng Z; Dai J; Kong Y; Guo J
Clin Sci (Lond); 2020 Jan; 134(2):193-205. PubMed ID: 31919521
[TBL] [Abstract][Full Text] [Related]
22. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Hilke FJ; Sinnberg T; Gschwind A; Niessner H; Demidov G; Amaral T; Ossowski S; Bonzheim I; Röcken M; Riess O; Garbe C; Schroeder C; Forschner A
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825510
[TBL] [Abstract][Full Text] [Related]
23. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Yuen KC; Liu LF; Gupta V; Madireddi S; Keerthivasan S; Li C; Rishipathak D; Williams P; Kadel EE; Koeppen H; Chen YJ; Modrusan Z; Grogan JL; Banchereau R; Leng N; Thastrom A; Shen X; Hashimoto K; Tayama D; van der Heijden MS; Rosenberg JE; McDermott DF; Powles T; Hegde PS; Huseni MA; Mariathasan S
Nat Med; 2020 May; 26(5):693-698. PubMed ID: 32405063
[TBL] [Abstract][Full Text] [Related]
24. Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.
Loupakis F; Maddalena G; Depetris I; Murgioni S; Bergamo F; Dei Tos AP; Rugge M; Munari G; Nguyen A; Szeto C; Zagonel V; Lonardi S; Fassan M
J Immunother Cancer; 2019 Nov; 7(1):297. PubMed ID: 31703605
[TBL] [Abstract][Full Text] [Related]
25. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Costa C; Wang Y; Ly A; Hosono Y; Murchie E; Walmsley CS; Huynh T; Healy C; Peterson R; Yanase S; Jakubik CT; Henderson LE; Damon LJ; Timonina D; Sanidas I; Pinto CJ; Mino-Kenudson M; Stone JR; Dyson NJ; Ellisen LW; Bardia A; Ebi H; Benes CH; Engelman JA; Juric D
Cancer Discov; 2020 Jan; 10(1):72-85. PubMed ID: 31594766
[TBL] [Abstract][Full Text] [Related]
26. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
[TBL] [Abstract][Full Text] [Related]
27. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models.
Ny L; Rizzo LY; Belgrano V; Karlsson J; Jespersen H; Carstam L; Bagge RO; Nilsson LM; Nilsson JA
Ann Oncol; 2020 Feb; 31(2):266-273. PubMed ID: 31959343
[TBL] [Abstract][Full Text] [Related]
28. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
29. Getting under the skin: The role of CDK4/6 in melanomas.
Guo L; Qi J; Wang H; Jiang X; Liu Y
Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436
[TBL] [Abstract][Full Text] [Related]
30. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.
Müller A; Dickmanns A; Resch C; Schäkel K; Hailfinger S; Dobbelstein M; Schulze-Osthoff K; Kramer D
J Clin Invest; 2020 Nov; 130(11):5765-5781. PubMed ID: 32701505
[TBL] [Abstract][Full Text] [Related]
31. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.
Álvarez-Fernández M; Malumbres M
Cancer Cell; 2020 Apr; 37(4):514-529. PubMed ID: 32289274
[TBL] [Abstract][Full Text] [Related]
33. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Vilgelm AE; Saleh N; Shattuck-Brandt R; Riemenschneider K; Slesur L; Chen SC; Johnson CA; Yang J; Blevins A; Yan C; Johnson DB; Al-Rohil RN; Halilovic E; Kauffmann RM; Kelley M; Ayers GD; Richmond A
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413145
[TBL] [Abstract][Full Text] [Related]
34. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
35. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.
Newell F; Wilmott JS; Johansson PA; Nones K; Addala V; Mukhopadhyay P; Broit N; Amato CM; Van Gulick R; Kazakoff SH; Patch AM; Koufariotis LT; Lakis V; Leonard C; Wood S; Holmes O; Xu Q; Lewis K; Medina T; Gonzalez R; Saw RPM; Spillane AJ; Stretch JR; Rawson RV; Ferguson PM; Dodds TJ; Thompson JF; Long GV; Levesque MP; Robinson WA; Pearson JV; Mann GJ; Scolyer RA; Waddell N; Hayward NK
Nat Commun; 2020 Oct; 11(1):5259. PubMed ID: 33067454
[TBL] [Abstract][Full Text] [Related]
36. CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.
Garutti M; Targato G; Buriolla S; Palmero L; Minisini AM; Puglisi F
Cells; 2021 May; 10(6):. PubMed ID: 34071228
[TBL] [Abstract][Full Text] [Related]
37. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
38. Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI.
Liu C; Zhang Y; Gao X; Wang G
BMC Biol; 2023 Jul; 21(1):159. PubMed ID: 37468850
[TBL] [Abstract][Full Text] [Related]
39. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
40. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Ying J; Han W; Hu C; Ling Y; Chi Z; Cui C; Si L; Fang J; Zhou A; Guo J
Clin Cancer Res; 2021 Jan; 27(1):43-51. PubMed ID: 33109737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
